Efficacy and safety of @entity3400 / XXXX in skin and soft tissue infections.

@entity1 @entity6 @entity7120 @entity798 @entity4967 @entity272 @entity3400
@entity3400 / @entity7120 has excellent in vitro activity against the most pathogens involved in @entity272 . Two large multicentre studies recently evaluated the efficacy and safety of @entity3400 / @entity7120 in the treatment of skin and soft tissue infections in @entity1 in hospital. The efficacy and safety of @entity3400 / @entity7120 (4 g/500 mg every 8 hours) have been assessed in an open study in Europe. Among 120 evaluable @entity1 , 93% were clinically cured or improved. Only six @entity1 were withdrawn from the study because of side effects. In another trial, @entity3400 / @entity7120 were compared with @entity4967 / @entity798 in a double-blinded prospective study in the United States. Of evaluable @entity1 , 67 received @entity3400 / @entity7120 (3 g/375 mg every 6 hours) and 44 received @entity4967 / @entity798 (3 g/100 mg every 6 hours). At assessment, 76% of @entity1 given @entity3400 / @entity7120 and 77% of @entity1 given @entity4967 / @entity798 had responded favourably. The lower success rate in this trial may be attributed to more stringent inclusion criteria that resulted in the incorporation of a higher proportion of @entity1 with more severe conditions including @entity6 . The incidence of adverse reactions was similar in both groups. @entity3400 / @entity7120 seems to be both effective and safe in the treatment of skin and soft tissue infections in @entity1 confined to hospital.
